- Contact Us
The world’s largest human pluripotent stem cell (hPSC) bank at Coriell is now open. This new collection will enable basic research, disease modeling and drug development. The first 300 lines available this month will expand to 750 lines by February 2016.
The common diseases and disorders represented in the new CIRM hPSC Repository at Coriell include: Cardiomyopathies; Autism Spectrum Disorder, Cerebral Palsy, Epilepsy, Intellectual Disability; Idiopathic Pulmonary Fibrosis; Hepatitis C, Fatty Liver Disease; Age-Related Macular Degeneration, Primary Open Angle Glaucoma, Diabetic Retinopathy; and Alzheimer’s disease.
Click here to learn more about the collection.
The mission of the Stem Cell Biobank (SCB) at the Coriell Institute for Medical Research is to provide scientists with the opportunity to bank their pluripotent stem cell lines at the SCB, and to develop in-house induced pluripotent stem cell (iPSC) lines for distribution to researchers. Established in 2008, the SCB has developed core capabilities to maintain, characterize, bank, and distribute important stem cell resources. The SCB performs extensive identification and characterization testing for all submitted human induced pluripotent stem cell (iPSC) and mouse embryonic stem cell (mES) lines. The identification and quality control measures include karyotype analysis, microsatellite analysis for parental cell line identity matching, sterility testing, and assessment of viability after cryopreservation. Pluripotency characterizations performed by SCB vary depending upon the distributing repository.
|NIGMS iPSCs||NIA mES|